The approval of GLP-1 class weight-loss drugs has sparked a revolution in obesity treatment, offering new hope for patients and reshaping the future of healthcare. With injectable weight-loss drugs gaining widespread popularity, the anti-obesity drug market is experiencing significant growth, and the possibilities for future treatments are more promising than ever.

In this Industry Pulse Report, we explore how the rise of injectable weight-loss drugs is transforming obesity care. We also dive into the latest research on genetic factors contributing to obesity, and how expanding access to these drugs could save countless lives. Download this report to learn key insights and:

• Explore the effectiveness and sustainability of injectable weight-loss drugs.
• Discover how expanded access to treatment can improve patient outcomes and save lives.
• Gain insight into groundbreaking research on the genetic factors behind obesity.